Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital and all investors from the company\u2019s July 2019 Series A financing, including LSP, Novo Ventures, Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Turenne Capital and Credit Agricole Creation.<\/p>\n
Amolyt plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404. In addition, the company continues to work to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.<\/p>\n
\u201cWe are very pleased to expand our high-quality syndicate with the addition of these new North American and European investors, and we are highly appreciative of the continued support from our existing investors<\/em>,\u201d stated Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma. \u201cThis financing will give us the opportunity to further pursue our mission of building a leading rare endocrine and related disease company, and we will continue to work to introduce new and potentially life-changing therapeutics to patients globally<\/em>.\u201d<\/p>\n <\/p>\n “We are very pleased to join Amolyt, which is led by a dynamic and experienced serial entrepreneur in the development of therapies targeting rare endocrinological and metabolic diseases. We are confident in the development of the lead product and in the team’s ability to create a high-quality pipeline to address major unmet medical needs in the field of endocrinology. The Life Sciences team is proud to co-lead this $80M round, which is a testimony to the dynamism of the sector in France and Europe, in collaboration with high quality investors and sector specialists,” said Rapha\u00ebl Wisniewski, Partner at Andera Life Sciences. <\/em><\/p>\n <\/p>\n The Series B financing follows several recent positive pipeline developments, including the following:<\/p>\n Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital and all investors from the company\u2019s July 2019…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-8135","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\n\n